# Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR

> **NCT01611298** · NA · COMPLETED · sponsor: **Robert Krance** · enrollment: 7 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndrome
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Tetanus

## Key facts

- **NCT ID:** NCT01611298
- **Lead sponsor:** Robert Krance
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-11
- **Final completion:** 2013-07
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01611298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01611298, "Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01611298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*